



# 2012 APEC Advanced Workshop of Good Review Practice relating to Medical Devices

## Session D: CRITICAL THINKING AND DECISION MAKING 8 November 2012 - Taipei

Insight on some European ideas

Laurent SELLES  
Health Technology and Cosmetics  
European Commission



# CRITICAL THINKING MEANS...

## Dealing with several conflicting objectives

- High level of protection of human health and safety
- Better functioning of EU single market
- Support of innovation
- Support of competitiveness of industry
- International convergence

# CRITICAL THINKING MEANS...

To have clear ideas on a number concepts:

- **Scope**
- **Role of economic operators**
- **Traceability**
- **Transparency**
- **Classification**
- **Conformity assessment**
- **General safety and performance requirements**
- **Clinical data**
- **Vigilance and market surveillance**
- **Role of standards**
- **Governance**

# CRITICAL THINKING MEANS...

**Role of economic operators: clear set of obligations and responsibilities**

## Manufacturers

- Quality management system
- Post-market surveillance plan
- Technical documentation/STED
- Qualified person

## Authorised representatives

- Written mandate
- Minimum tasks
- Qualified person




# CRITICAL DECISION MAKING MEANS...

## Tightened supervision of Notified bodies:

- Reinforced minimum requirements (independence, impartiality, competence, resources and processes)
- New process for designation and monitoring ('joint assessments')
- Scrutiny mechanism applicable to high-risk devices
  - Early information
  - Possibility to check in individual cases the preliminary conformity assessment



European Commission





# CRITICAL DECISION MAKING MEANS...

## For the conformity assessment

- Annual surveillance audits
- Unannounced factory inspections and sample testing
- Rotation of auditors



# CRITICAL THINKING MEANS...

## *Special procedures for Conformity assessment*

- For MD with ancillary medicinal substance: streamlined consultation of pharmaceutical authority
- For human tissue engineered MD: consultation of authority responsible for human tissues & cells
- For companion diagnostics: consultation of pharmaceutical authority (personalized medicine)

# CRITICAL THINKING MEANS...

## Regarding Clinical data

### Clinical investigations

- Streamlined procedures, aligned with proposed rules on clinical trials on medicinal products
- Option for single application by sponsor in case of multi-Member State studies
- Always required for class III and implantable MD

### Clinical evaluation

- Continuous process, incl. post-market clinical follow-up



# CRITICAL THINKING MEANS...

## Regarding Vigilance and Market Surveillance

### Vigilance

- EU vigilance portal
- Central reporting of serious incidents and field safety corrective actions
- Reporting of FSCA outside EU regarding devices placed also on the EU market
- Trend reporting (for classes IIb/C and III/D)
- Enhanced coordination between authorities
- Extended role of notified bodies



# CRITICAL THINKING MEANS...

## Better Vigilance and Market Surveillance

### Market surveillance

- Clearer rights and obligations of market surveillance authorities (e.g. in-market controls)
- Clearer procedures for national provisional measures (e.g. safeguard clause, corrective actions against non-compliant products)
- Mutual information and control



# CRITICAL THINKING MEANS...

## Regarding “Governance”:

### Reinforced coordination

- **Medical Device Coordination Group**
  - Experts representing national authorities (MD and IVD)
  - European Commission: chair

### Technical, scientific and logistic support

- **European Commission: DG SANCO & Joint Research Centre**



# CRITICAL THINKING MEANS...

**RECOGNIZING** that implementation of existing legislation needs improvement:

## Notified bodies

- Harmonized designation and monitoring by Member States (Commission Regulation under preparation)
- Review of existing designations
- Best practices for conformity assessment by notified bodies (Commission Recommendation under preparation)



# CRITICAL DECISION MAKING MEANS...

## Looking for *Scientific expertise*

- Mandates to the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) on
  - PIP silicone breast implants
  - Metal-on-metal hip joint replacements
- Support from European Commission's in-house science service



## Further information

- Website of the European Commission:  
[http://ec.europa.eu/health/medical-devices/  
index\\_en.htm](http://ec.europa.eu/health/medical-devices/index_en.htm)
- Functional mailbox of the medical devices' unit:  
sanco-cosmetics-and-medical-devices[at]ec.europa.eu